



FOR IMMEDIATE RELEASE

Organamet Bio Inc
430 S Decatur Street
Montgomery AL 36104
Email: doris.taylor@organametbio.com
Phone: (713)-882-9945

Organamet Bio Inc
c/o ARMI | BioFabUSA Technology Center
400 Commercial Street
Manchester NH 03101
USA

Organamet Bio offers congratulations to the University of Maryland and United Therapeutics on their historic transplant of a pig heart into a heart failure patient who otherwise could not receive a human heart transplant. This groundbreaking accomplishment is a long-awaited culmination of a 40-year discovery process.

This step forward demonstrates the huge unmet need: So few human hearts are available that patients are willing to receive a pig heart, not knowing if or how long it may last. It also shows the promise of regenerative medicine in solving the unmet need for organs for transplant.

Dr. Doris Taylor, CEO of Organamet Bio, stated, “A pig heart transplant has been anticipated for a few years now – and is a thrill to see. At the same time, the need for immunosuppression to prevent rejection remains a major financial and medical hurdle for these patients. We all greatly look forward to the day enough human hearts are available for transplant. The world of regenerative medicine is rapidly accelerating, and Organamet Bio is thrilled to be a contributor to the future that includes bioengineering autologous human hearts that will overcome these final hurdles to having enough organs to treat the No. 1 killer of men women and children worldwide.”

Organamet Bio Inc., with R&D and manufacturing headquartered in Manchester, NH, at ARMI | BioFabUSA, is developing autologous human hearts (Your-Heart™ Solution) to be used for transplant. Your-Heart™ Solution takes heart transplant from a time-constrained emergency surgery to a scheduled procedure. It also eliminates the need for anti-rejection drugs, reduces patient costs and, more importantly, extends patient’s lives. The company has assembled an international team, including the technology inventor whose prior company successfully exited earlier this year, with global leaders in regenerative medicine, cardiovascular disease, biotech manufacturing and intellectual property.

Organamet Bio Inc., is a strategic partner of the Advanced Regenerative Manufacturing Institute (ARMI). ARMI is a member-based, non-profit organization funded by the United States Department of Defense. ARMI’s mission is to make practical the scalable, consistent and cost-effective manufacturing of tissue-engineered medical products and tissue-related technologies.